epiClinicalA fictional CRO

epiClinical is fictional. It is a portfolio demonstration by Adam Daniels. Its studies, sponsors, sites and enrolment figures are synthetic. The evidence behind its assumptions is real, and every number says how far it can be trusted.

EPI-301, Phase III. Recruiting

Non-small cell lung cancer, second line

NWT-4471 with docetaxel against docetaxel alone in previously treated non-small cell lung cancer. Sponsor: Northwind Therapeutics (fictional), Oncology.

When will this study finish recruiting? Set its sites yourself, or let the planner find the fewest per country that meet the deadline.

Study and plan

Northwind Therapeutics (fictional), Phase III, Oncology. Month 0 is January 2025.
Randomise 400 (drop-out 15%) and screen about 667 (screen failure 40%)
Jan 2028
Confidence wanted
Sites per country
Edit the site counts in the table below
How much sites differ
Spread of site rates (coefficient of variation 0.9). Fitted trials range from 0.7 to 1.2.
  • Central finish (P50)Aug 2027month 31.5
  • Fast case (P10)Mar 2027month 26.4
  • Slow case (P90)Mar 2028month 38.7
  • Chance of meeting the deadline80%wanted 85%
  • Sites15926% likely to recruit nobody
  • Patients to screen667to randomise 400

On course to finish in August 2027, five months before the deadline

EPI-301, patients randomised, cumulative by monthThe band holds 80% of 4,000 simulated studies; the coloured line is the central forecast; the line marked Actual is recruitment so far

Show data
Patients randomised by month: fast, central and slow cases of the simulation, and actual recruitment
MonthFast caseCentralSlow caseActual
Jan 20250000
Apr 20250000
Jul 20254201
Oct 202525171012
Jan 202668503545
Apr 2026128977080
Jul 2026198150111124
Oct 2026271207153171
Jan 2027341261195–
Apr 2027400317236–
Jul 2027400372278–
Oct 2027400400319–
Jan 2028400400362–
Apr 2028400400400–
Jul 2028400400400–
Oct 2028400400400–
Jan 2029400400400–

Source: epiClinical Poisson-gamma simulation; actual recruitment to September 30th 2026. All data synthetic.

How likely is it to finish by a given month?

A four-in-five chance of finishing by January 2028

Finish month of 4,000 simulated studiesOne dot = 40 simulated studies · 80 of 100 dots finish in time

Drag the handle or
In time: 80%Median Aug 2027Late: 20%

Source: epiClinical Poisson-gamma simulation

Show data
Chance that recruitment is complete by the end of each month
MonthChance complete by then
Jan 20250%
Apr 20250%
Jul 20250%
Oct 20250%
Jan 20260%
Apr 20260%
Jul 20260%
Oct 20260%
Jan 20272%
Apr 202714%
Jul 202737%
Oct 202762%
Jan 202880%
Apr 202891%
Jul 202896%
Oct 202898%
Jan 202999%

Countries

UseCountryPatients per site per monthSites open betweenCapSitesPatients by finish
United States
0.091
  • Therapeutic area: 0.350 Oncology baseline
  • Country: ×0.75 United States
  • Site type: ×0.988 Usual mix in United States
  • Track record: ×0.98 Expected mix for mostly repeat sites
  • Protocol and population: ×0.48 Moderately restrictive eligibility ×0.8, Second line ×0.6
  • Patient acceptability: ×1 No effect from the answers
  • Competing trials: ×0.75 Heavy competition ×0.75
month 4.1 to 10.2 100110
United Kingdom
0.102
  • Therapeutic area: 0.350 Oncology baseline
  • Country: ×0.85 United Kingdom
  • Site type: ×0.975 Usual mix in United Kingdom
  • Track record: ×0.98 Expected mix for mostly repeat sites
  • Protocol and population: ×0.48 Moderately restrictive eligibility ×0.8, Second line ×0.6
  • Patient acceptability: ×1 No effect from the answers
  • Competing trials: ×0.75 Heavy competition ×0.75
month 4.0 to 10.0 4462
Spain
0.121
  • Therapeutic area: 0.350 Oncology baseline
  • Country: ×1 Spain
  • Site type: ×0.977 Usual mix in Spain
  • Track record: ×0.98 Expected mix for mostly repeat sites
  • Protocol and population: ×0.48 Moderately restrictive eligibility ×0.8, Second line ×0.6
  • Patient acceptability: ×1 No effect from the answers
  • Competing trials: ×0.75 Heavy competition ×0.75
month 7.6 to 13.6 7187
Poland
0.178
  • Therapeutic area: 0.350 Oncology baseline
  • Country: ×1.4 Poland
  • Site type: ×1.028 Usual mix in Poland
  • Track record: ×0.98 Expected mix for mostly repeat sites
  • Protocol and population: ×0.48 Moderately restrictive eligibility ×0.8, Second line ×0.6
  • Patient acceptability: ×1 No effect from the answers
  • Competing trials: ×0.75 Heavy competition ×0.75
month 11.1 to 17.1 4176
Turkey
0.119
  • Therapeutic area: 0.350 Oncology baseline
  • Country: ×1 Turkey
  • Site type: ×0.965 Usual mix in Turkey
  • Track record: ×0.98 Expected mix for mostly repeat sites
  • Protocol and population: ×0.48 Moderately restrictive eligibility ×0.8, Second line ×0.6
  • Patient acceptability: ×1 No effect from the answers
  • Competing trials: ×0.75 Heavy competition ×0.75
month 6.0 to 12.0 1832
India
0.129
  • Therapeutic area: 0.350 Oncology baseline
  • Country: ×1.1 India
  • Site type: ×0.952 Usual mix in India
  • Track record: ×0.98 Expected mix for mostly repeat sites
  • Protocol and population: ×0.48 Moderately restrictive eligibility ×0.8, Second line ×0.6
  • Patient acceptability: ×1 No effect from the answers
  • Competing trials: ×0.75 Heavy competition ×0.75
month 6.0 to 12.0 1534

Country risks to weigh when choosing sites

United States

Two sourced risks

  • All sites

    The first US site opens quickly, but the rest of the US sites open slowly.

    The US activates its first site quickly but scales its site fleet slowly · PM-03 · grade B

    Tightens: site activation overdue

  • All sites

    Under-represented groups need a plan from the start; diversity action plans apply to Phase III studies.

    Racial and ethnic under-representation · PB-12 · grade A

United Kingdom

Two sourced risks

  • Some sites

    Costing and contracting were the longest start-up step; the national contract has shortened it.

    Fragmented, negotiated costing and contracting · POL-03 · grade A

  • If it recurs

    The regulator's backlog of 2023 was cleared, but could recur.

    Regulator assessment backlog · POL-02 · grade A

Spain

Two sourced risks

  • All sites

    Site contracts took 117 days in 2016 and about 90 after national templates.

    Fragmented, negotiated costing and contracting · POL-03 · grade A

  • All sites

    Applications go through the EU Clinical Trials Regulation and its portal.

    Regional regulatory transition friction (EU CTR and CTIS) · POL-15 · grade A

Poland

Two sourced risks

  • All sites

    Applications go through the EU Clinical Trials Regulation and its portal.

    Regional regulatory transition friction (EU CTR and CTIS) · POL-15 · grade A

  • All sites

    A central ethics committee reviews every study; its effect on timelines is not measured.

    Ethics-committee structure (random CPP allocation, 40 Italian territorial committees, a central Polish committee, Denmark's timeliness) · POL-20 · grade B

Turkey

Four sourced risks

  • All sites

    Ethics committees fell from 145 to 49 in 2024, cutting review capacity.

    Ethics-committee re-registration or re-constitution that cuts review capacity (India 2013; Turkey 2024) · RW-05 · grade B

    Tightens: site activation overdue

  • All sites

    A fixed pharmaceutical exchange rate has caused repeated medicine shortages.

    Currency crisis with a fixed pharmaceutical exchange rate (Turkey 2018–2026) · RW-07 · grade D

    Tightens: study drug at the site

  • All sites

    Start-up time has not been measured since CRO data from 2014 and 2015.

    Start-up time for India and Turkey is unmeasured · PM-04 · grade C

  • If it recurs

    Sites in the south-east lie in the 2023 earthquake zone.

    Major earthquake in a site region · SH-11 · grade C

India

Two sourced risks

  • All sites

    Vulnerable participants in trials of new drugs need an audio-visual record of their consent.

    Mandatory audio-visual consent for all participants · RW-03 · grade C

    Tightens: consent findings

  • All sites

    Start-up time is unmeasured beyond the statutory 90 working days.

    Start-up time for India and Turkey is unmeasured · PM-04 · grade C

    Tightens: site activation overdue

Risk-register entries; the choice of entries per country is epiClinical's.